Sarah Quinn
Nurse Practitioner · Reno, NVNPI 1891126512
Payments from drug & device makers
Across 60 payments — averaging $58.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$2K
- Amgen$383
- Vifor Pharma, Inc.$364
- GSK$223
- AstraZeneca$198
- Otsuka America Pharmaceutical, Inc.$108
- plus $512 from 17 others
What the payments were for
- Food & beverage$1,77399%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 9 | $1,697 |
| Amgen(2 entities) | 11 | $383 |
| Vifor Pharma, Inc. | 6 | $364 |
| GSK | 2 | $223 |
| AstraZeneca | 6 | $198 |
| Otsuka America Pharmaceutical, Inc. | 4 | $108 |
| Boehringer Ingelheim | 1 | $106 |
| Mallinckrodt Hospital Products Inc. | 3 | $62 |
| Calliditas Therapeutics US Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Fresenius USA Marketing, Inc. | 2 | $26 |
| Travere Therapeutics, Inc. | 2 | $26 |
| Bayer | 1 | $24 |
| Abbott | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| UCB, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,484 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 16 | $30,856 |
| Lanthanum Carbonate | 11 | $13,907 |
| Sevelamer Carbonate | 20 | $3,773 |
| Cinacalcet Hcl | 14 | $2,219 |
| Potassium Chloride | 31 | $858 |
| Allopurinol | 26 | $299 |
| Furosemide | 29 | $287 |
| Torsemide | 11 | $242 |
| Losartan Potassium | 23 | $175 |
| Carvedilol | 17 | $140 |
| Tamsulosin Hcl | 11 | $139 |
| Gabapentin | 12 | $116 |
| Calcitriol | 13 | $108 |
| Atorvastatin Calcium | 17 | $106 |
| Spironolactone | 15 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $26 | $30,85616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Reno
- Melissa DelamoraReno$20K
- Darian ThorpReno$18K
- Mary Beth MedinaReno$11K
- Kristen BowmanReno$10K
- Laura HayReno$8K
- Laura HarshReno$7K
- Mary HelmreichReno$7K
- Rhonda StrunkReno$7K
- Rachael HueftleReno$7K
- Rhonda NavarroReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.